$YARW News

Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate

BTIG Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $58

TD Cowen Initiates Coverage On Yarrow Bioscience with Buy Rating

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'

VYNE Therapeutics Announces 1-For-50 Reverse Stock Split, Effective July 24

VYNE Therapeutics Announces Special Cash Dividend Of $0.38/Share

VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.

VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

VYNE Therapeutics Enters All-Stock Merger With Yarrow Bioscience, Combined Co. Will Operate As Yarrow Bioscience

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate

VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

VYNE Therapeutics Q2 EPS $(0.13) Beats $(0.22) Estimate, Sales $69.000K Miss $150.000K Estimate